Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label pilot study of subcutaneous sarilumab in hospitalized patients with moderate-severe COVID-19
2020-001634-36Phase 2Completed
- Sponsor
- Rosario GarcÃa de Vicuña
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Sarilumab plus standard of care with Standard of care alone (2 arms). Primary endpoint: Time to sustained afebrile status (primary). Started Apr 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001634-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001634-36.